Tempus Announces Dr. Ned Sharpless as a Senior Strategic Advisor

Tempus, a leader in artificial intelligence and precision medicine, today announced that Norman E. “Ned” Sharpless, MD, will serve as a senior strategic advisor to Tempus and its leadership team, leveraging his vast experience as a medical policy expert and cancer researcher to further the company’s mission of improving patient outcomes.

Dr. Sharpless was most recently the Director of the National Cancer Institute (NCI), part of the National Institutes of Health, a position he held from 2017 to 2022. He also served as Acting Commissioner for Food and Drugs at the U.S. Food and Drug Administration (FDA) in 2019, before returning to the NCI directorship. At the NCI, Dr. Sharpless was instrumental in championing health equity and modernizing clinical trials, among many other accomplishments. Prior to the NCI, he was the director of the UNC Lineberger Comprehensive Cancer Center.

“Dr. Sharpless has had an indelible impact on the medical community in addressing major public health challenges and spurring innovation,” said Eric Lefkofsky, Founder and CEO of Tempus. “His vast experience in healthcare, and more specifically the oncology space, is invaluable and we are thrilled to have him as an advisor.”

“I’m excited to join the Tempus team and to advance the use of multimodal data to improve the care of adults and children with cancer,” said Dr. Sharpless. “The breadth and depth of the Tempus platform presents a unique opportunity to both identify increasingly personalized treatments and help target our research to focus on the most promising of the next generation of therapeutics for cancer patients.”

Dr. Sharpless received his medical degree from the University of North Carolina (UNC) School of Medicine, and completed his clinical training at Massachusetts General Hospital and the Dana-Farber Cancer Institute, both of Harvard Medical School. He is the Professor of Cancer Policy and Innovation at the UNC School of Medicine, co-Founder of Jupiter BioVentures, and a member of the American Association of Physicians and the National Academy of Medicine.

About Tempus
Tempus is a technology company advancing precision medicine through the practical application of artificial intelligence in healthcare. With one of the world’s largest libraries of clinical and molecular data, and an operating system to make that data accessible and useful, Tempus provides AI-enabled precision medicine solutions to physicians to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics. The goal is for each patient to benefit from the treatment of others who came before by providing physicians with tools that learn as the company gathers more data. For more information, visit

Related Content

View more
  • post image

    Tempus’ FDA approval and insights on the use of companion diagnostics in clinical development

    Tempus has recently announced the PMA approval for xT CDx, our solid tumor CDx and 648 gene panel.

    In this webinar, you will hear how the Tempus platform can support development of new therapies by combining real-world data, next-generation sequencing, and artificial-intelligence to advance precision oncology. Our regulatory and scientific experts will provide an overview of the pathways for diagnostics and share best practices for biopharma and biotech sponsors to consider in clinical trial design and the development of companion diagnostics.

    Watch replay
  • post image

    Using TIME to accelerate trial enrollment for Aadi Bioscience

    The Tempus TIME program provided Aadi access to a network of providers and patients to accelerate enrollment for its PRECISION 1 TSC1/TSC2 phase 2 clinical trial. Read on to learn how the TIME program decreased time to enroll with the just-in-time activation of ~10 business days.

    Read more
  • post image

    Increasing PTS using multimodal data

    Learn how AstraZeneca employs multimodal data to increase the probability of technical success of all Phase 3 oncology studies.

    Watch replay